Just weeks after Novo Nordisk introduced that its weight problems drug Wegovy minimize the chance of coronary heart problems in a serious trial, the corporate now has outcomes from a unique examine exhibiting the remedy may also profit individuals with a standard sort of coronary heart failure.
The outcomes, printed Friday within the New England Journal of Medication, discovered that amongst individuals with weight problems and coronary heart failure with preserved ejection fraction, or HFpEF, these taking Wegovy skilled better enhancements in signs and bodily perform in contrast with these on placebo. The enhancements have been better than what’s been seen in trials of another HFpEF therapies.
Novo beforehand shared topline ends in investor calls, however the brand new examine accommodates the total findings, that are additionally being offered on the European Society of Cardiology convention this week.
Unlock this text by subscribing to STAT+ and luxuriate in your first 30 days free!
GET STARTED